Veru Inc. (VERU) stock
VERUNasdaqPharmaceutical PreparationsFiscal year ends September 30
$2.31+0.17 (+7.94%)
Close on Nov 18, 2026Market cap $39.39MP/E –Yield –
Veru operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Veru's operating income for the twelve months ending Jun 30, 2026 was -$19.19M. For fiscal 2025 it was -$24.75M. The highest annual figure on record is $12.97M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -$24.75M | – |
| FY2024 | Sep 30, 2024 | -$36.17M | – |
| FY2023 | Sep 30, 2023 | -$93.78M | – |
| FY2022 | Sep 30, 2022 | -$83.49M | -743.6% |
| FY2021 | Sep 30, 2021 | $12.97M | – |
| FY2020 | Sep 30, 2020 | -$14.75M | – |
| FY2019 | Sep 30, 2019 | -$6.44M | – |
| FY2018 | Sep 30, 2018 | -$20.87M | – |
| FY2017 | Sep 30, 2017 | -$8.49M | -381.4% |
| FY2016 | Sep 30, 2016 | $3.02M | -54.4% |
| FY2015 | Sep 30, 2015 | $6.62M | +68.7% |
| FY2014 | Sep 30, 2014 | $3.92M | -59.9% |
| FY2013 | Sep 30, 2013 | $9.79M | -10.5% |
| FY2012 | Sep 30, 2012 | $10.94M | +232.0% |
| FY2011 | Sep 30, 2011 | $3.30M | -24.2% |
| FY2010 | Sep 30, 2010 | $4.35M | -7.8% |
| FY2009 | Sep 30, 2009 | $4.72M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$7.71M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$7.22M | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$5.42M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $1.17M | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$7.55M | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -$8.12M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$10.25M | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$9.34M | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$10.55M | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$8.89M | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$7.39M | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$8.18M | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -$13.74M | – |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -$34.41M | – |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$37.45M | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$44.94M | – |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -$21.82M | – |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -$11.76M | – |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$4.96M | -125.9% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$1.87M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -$2.87M | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -$1.47M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $19.19M | – |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$11.27M | – |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$1.39M | – |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -$299.68K | – |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -$1.78M | – |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | -$1.46M | – |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -$1.84M | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -$2.12M | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | -$1.01M | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -$3.77M | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -$4.96M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$4.70M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -$7.44M | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -$2.77M | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$1.27M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$2.58M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -$1.87M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$292.99K | – |
See a number that looks wrong?